Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > European Commission Decision on Carlye/Vantive Merger

<< Previous

Bullboard Posts

Next >>

Comment by gebremeskelon Oct 23, 2024 5:10pm

59 Views

Post# 36279264

RE:European Commission Decision on Carlye/Vantive Merger

Actually, the EC was notified on 21Oct24 not 10Oct24

gebremeskel wrote: If I'm reading this correctly the EC was notified about the prospective Carlye/Vantive merger on 10Oct24 and will make their decision to allow or disallow (provisionally) by 26Nov24.

https://competition-cases.ec.europa.eu/cases/M.11732?from=latest-updates&caseInstrument=M&dateHighlight=2024-10-23

The issue to be decided is to whether or not the merger will impede the proper functioning of the EU's internal market by reducing competition.

https://www.europarl.europa.eu/factsheets/en/sheet/82/competition-policy

Description of the concentration:

https://ec.europa.eu/competition/mergers/cases1/202443/M_11732_10306117_204_3.pdf